

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO.: OC01626K

APPLICATION NO.:

10/666.424 APPLICANT: INFORMATION DISCLOSURE STATEMENT Kamil Paruch et al. BY APPLICANT FILING DATE: GROUP: (Use several sheets if necessary) 09/19/2003 U.S. PATENT DOCUMENTS *EXAMINER DOCUMENT DATE NAME CLASS SUB-FILING DATE IF INITIAL **NUMBER** CLASS **APPROPRIATE** AW AX AY ΑZ BA BB BC BD BE BF BG FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-TRANSLATION **NUMBER CLASS** YES NO BH WO 02/10162 02/07/2002 **WIPO** ВΙ BJ BK BL OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) A. Sanderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", J. Clin. Oncology, 16: 2986-2999 (1998). J. Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", Eur. J. Biochem., BN 224: 771-786 (1994). BO I. Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5", Eur. J. Biochem., 243: 527-536 (1997). K. S. Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", J. Medicinal Chemistry, 45: 3905-3927 (2002)BQ BR **EXAMINER** DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JOJ	8
MAR 3 1 2004	OFFICE
FORM PLOTE	<u>5/</u>

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: OC01626K

APPLICATION NO.: 10/666,424

INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT: Kamil Paruch et al.				
(Use several sheets if necessary))	FILING DATE: 09/19/2003		GROUP:			
			U.S. PATE	ENT DOCU	MENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	N	AME	CLASS	SUB- CLASS	FILING	
	AA								
	AB						İ		•
	AC			1					
	AD								
	AE			<u> </u>	· · · · · · · · · · · · · · · · · · ·		<u> </u>		
	AF						<u> </u>		
	AG			i	· · · · · · · · · · · · · · · · · · ·		†	1	
	AH								
	Al			· · · · · · · · · · · · · · · · · · ·					
*****	AJ			<u> </u>					
								<u> </u>	
	AK					l			
		FC DOCUMENT NUMBER	PREIGN PA	ATENT DOC	CUMENTS	CLASS	SUB- CLASS	TRANS	SLATION I NO
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUB- CLASS		
	AK	DOCUMENT		COUNTRY	CUMENTS	CLASS			
	AK	DOCUMENT NUMBER	DATE	COUNTRY		CLASS			
	AK AL AM	DOCUMENT NUMBER	DATE	COUNTRY		CLASS			
	AL AM AN	DOCUMENT NUMBER	DATE	COUNTRY		CLASS			
	AL AM AN AO AP	DOCUMENT NUMBER WO 2002 060492 A	08/08/2002	COUNTRY	/IPO		CLASS	YES	
	AL AM AN AO AP	DOCUMENT NUMBER	08/08/2002	COUNTRY	/IPO		CLASS	YES	
	AL AM AN AO AP OTI	DOCUMENT NUMBER WO 2002 060492 A	08/08/2002	COUNTRY	/IPO		CLASS	YES	
	AL AM AN AO AP OTH AQ AR	DOCUMENT NUMBER WO 2002 060492 A	08/08/2002	COUNTRY	/IPO		CLASS	YES	
	AL AM AN AO AP OTI AQ AR AS	DOCUMENT NUMBER WO 2002 060492 A	08/08/2002	COUNTRY	/IPO		CLASS	YES	
	AK AL AM AN AO AP OTI	DOCUMENT NUMBER WO 2002 060492 A	08/08/2002	COUNTRY	/IPO		CLASS	YES	
	AL AM AN AO AP OTI AQ AR AS	DOCUMENT NUMBER WO 2002 060492 A	08/08/2002	COUNTRY	/IPO		CLASS	YES	SLATION
	AK AL AM AN AO AP OTI	DOCUMENT NUMBER WO 2002 060492 A	08/08/2002	Author, Titl	/IPO		CLASS	YES	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.